PREM MAHENDRA

    Consultant Haematologist in Birmingham, UK
Consultant Haemato-Oncologist London

Publications

 
  • Dignan FL, Clark A, Amrolia P, J Cornish, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Shaw BE and Potter MN.
    Diagnosis and management of chronic graft versus host disease.
    British Journal of Haematology 2012; 158; 40-45


  • Dignan FL, Amrolia P, A Clark, J Cornish, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Shaw BE and Potter MN.
    Diagnosis and management of chronic graft versus host disease.
    British Journal of Haematology 2012; 158; 46-61


  • Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, , Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Shaw BE and Potte. MN.
    Organ-specific management and supportive care in chronic graft versus host disease.
    British Journal of Haematology 2012; 158; 62-78.


  • CD8+ T cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for graft versus lekemia.
    McLarnon A, Piper KP, Goodyear OC, Arrazi J, Mahendra P, Cook M, Clark F, Pratt G, Craddock C, Moss P.
    Haematologica 2010 [Epub ahead of print]

  • Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols
    Tauro S, Cochrane, L, Lauritzsen GF, Barker L, Delabie J, Roberts C, Mahendra P, Holte H.
    Am J Hematol 2010; 85; 261-3

  • Lokare A, Chaganti S, Lipkin G, Roberts C, Mahendra P
    Posttransplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient.
    Transplantation 2008; 85; 1219-1210.

  • Head and neck lymphomas
    Mahendra P
    In Stell and Maran's Textbook of Head and Neck, 2008. Editors Watkinson J and Gilbert R

  • The role of rituximab post stem cell transplantation.
    Tawana K and Mahendra P
    Lymphoma Forum, November 2007, epub

  • CXC10-CXCR3 interactions play an important role in the pathogenesis of acute GvHD in the skin following allogeneic stem-cell transplantation.
    Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicolls S, Mahendra P, Craddock C, Moss PAH Blood, 2007; 110; 3827-3832

  • Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs K, Sureda A, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera J, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone A, Alvarez A, Linch D, Sierra J, Mackinnon S.
    British Journal of Haematology, 2007; 139; 70-80.

  • Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.
    Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P.
    Blood; 2006; 107: 1230-1232

  • Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation.
    Karanth M, Begum G, Cook M, Porter C, Lister N, Gray J, Lawson S, Darbyshire P, Craddock C, Mahendra P
    Bone Marrow Transplantation, 2006; 37: 419-423

  • Tauro S, Craddock C, Peggs K, Begum G, Chopra R, Littlewood T, Parker A, Marsh J, Cook G, Hale G, Snowdon J, Milligan D, Hunter A, Russell N, Goldstone A, Mahendra P, Linch D, Mackinnon S
    Outcome of allogeneic stem cell transplantation in adults with high risk acute myeloid leukaemia and myelodysplasia using an alemtuzemab based reduced-intensity conditioning regimen.
    Journal of Clinical Oncology, 2005; 23; 9387-9393

  • CD8+ T cells specific for cancer-germline gene antigens are found in many patients with multiple myeloma and their frequency correlates with disease burden.
    Goodyear O, Piper K, Khan N, Starczynski, Mahendra P, Pratt G, Moss P
    Blood, 2005; 106; 4217-4224

  • Cobbold M, Khan N, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss P.
    Direct adoptive transfer of CMV-specific CTL to stem cell transplant patients following selection by HLA-peptide tetramers.
    Journal of Experimental Medicine, 2005: 202; 379-386

  • Wandroo FA, Mahendra P, Khuroo RA, Neilson J
    Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions.
    Clinical and Laboratory Haematology, 2005: 27: 203-205

  • Raj K, Narayanan S, Augustson B, Ho A, Mehta P, Duncan N, Tauro S, Mahendra P, Craddock C, Mufti G.
    Rituximab is effective in management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
    Bone Marrow Transplantation, 2005:35; 299-301.

  • Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams C, Cook G, Towlson K, Marks D, Russell NH.
    The effects of the conditioning regimen on outcome following allogeneic haemopoietic stem cell transplantation for myeloma
    British Journal for Haematology, 2005:128:496-502.

  • Peggs S, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Dogan A, Thomson K, Morris E, Hale G, Waldmann H, Goldstone A, Linch D, Mackinnon S.
    Clinical evidence of a graft-versus-Hodgkins lymphoma effect after reduced intensity allogeneic transplantation.
    Lancet, 2005:365:1934-41

  • "Floating" teeth at presentation in sporadic Burkitt's lymphoma.
    Murrin RJ, Mahendra P
    British Journal of Haematology, 2004: 127: 1

  • Successful allogeneic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection.
    Mehta P, Augustson, Krishnamurthy S, Jacob A, D Roy, Olliff J, Cook M, Craddock C, Mahendra P
    Bone Marrow Transplantation, 2004: 34:825-826

  • Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith G, Parker P, Schey S, Snowden J, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S.
    Outcome following Alemtuzumab (Campath-1H) containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkins lymphoma
    Blood, 2004, 104; 3865-71

  • Wandroo F, Augustson B, Cook M, Craddock C, Mahendra P
    Successful use of Campath-1H in the treatment of steroid refractory liver GvHD
    Bone Marrow Transplantation, 2004: 34: 285-7.

  • Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, Begum G, Mahendra P, Craddock C, Moss P, Chakraverty R.
    Chronic GvHD is associated with increased numbers of peripheral blood CD4+, CD25 high regulatory T cells.
    Blood, 2004, 103; 2410-2416

  • Cook MA, milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC.
    The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling haemopoietic stem cell transplantation for myeloid leukaemia.
    Blood, 2004, 103; 1521-1526.

  • Faulkner RD, Craddock CF, Bryne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Liu Yin J, Russell NH.
    BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferatice diseases: GvHD, toxicity and survival in 65 patients.
    Blood, 2004, 103; 428-434

  • Tauro S, Shankararanarayanan P, Nitu-Whalley IC, Duncan N, Begum G, Craig JI, Marcus RE, Craddock CF, Mahendra P.
    Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
    Bone Marrow Transplanation, 2003, 32; 273-278.

  • High-hyperploidy in Ph positive acute lymphoblastic leukaemia: case-report and review of literature.
    Tauro S, McMullan D, Griffiths M, Craddock C, Mahendra P.
    Bone Marrow Transplantation, 2003, 9; 763-766.

  • Tauro S, Clark FJ, Lipkin , Richards N, Mahendra P.
    Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failures.
    Bone Marrow Transplantation, Bone Marrow Transplantation; 2002; 30; 471-473

  • Clark FJ, Freeman L, Dzionek A, Schmitz J, McMullan, Simpson P, Mason J, Mahendra P, Craddock C, Griffiths M, Moss P, Chakraverty R.
    Origin and subset distribution of peripheral blood dendritic cells in patients with chronic GvHD.
    Transplantation 2003, 75, 221-225.

  • Peggs KS, Paneesha S, Kottaridis PD, Chakraverty RK, Tobias G, Reilly M, Mahendra P, Yong K.
    Peripheral blood stem cell transplantation for POEMS syndrome.
    Bone Marrow Transplantation, 2002, 30; 401-404

  • Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA
    Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
    Blood, 2002, 100; 224-229.

  • Chakrabarti S, Kottaridis PD, Peggs K, Ogormon P, Chakraverty R, Marshall T, Osman H, Gentle T, Mahendra P, Craddock C, Walderman H, Hale G, Fegan CD, Goldstone AH, Linch DC, Chopra R, Mackinnon S, Milligan DW.
    Reduced GvHD but a high incidence of cytomegalovirus infection and delayed reconstitution of T-cell subsets after nonmyeloablative haematopoietic stem cell transplants using Campath 1H (anti CD52 antibody)
    Blood, 2002, 12; 4357-4363

  • Beswick SJ, Jones EL, Mahendra P, Marsden JR
    Chloroma (aleukaemic leukaemia cutis) initially diagnosed as cutaneous lymphoma.
    Clinical and Experimental Dermatology, 2002, 27, 272-274.

  • Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfueth S, Geary J, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann, H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S.
    Limiting transplant-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen.
    Blood, 2002, 99, 1071-1078..

  • Harris E, Jackson N, Jones L, Mahendra P
    Burkitt's lymphoma: single centre experience with modified BFM protocol.
    Clinical and Laboratory Haematology, 2002, 24, 111-114.

  • Harris E, Mahendra P, Linch D, Chatterjee R.
    Gynaecomastia with hypogonadism and androgen oestrogen imbalance in recipients of high dose chemotherapy or chemoradiotherapy.
    Bone Marrow Transplantation, 2001, 28, 1141-1144.

  • Lush RJ, Haynes AP, Byrne JL, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Liu Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.
    Allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with donor lymphocyte infusion.
    Cryotherapy 2001, 3, 203-210.

  • Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JCW, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.
    In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem cell transplantation. Cryotherapy, 2001, 3, 197-201.

  • Zaidi Y, Hastings M, Murray J, Rowena JM Kursheid M, Mahendra P.
    Quinolone resistance in neutropenic patients in 2 very different haematology units.
    Clinical and Laboratory Haematology, 2001, 23, 39-4

  • Tauro S and Mahendra P
    Resolution of sarcoidosis post-allogeneic bone marrow transplantation with donor lymphocyte infusions.
    Bone Marrow Transplantation, 2001, 27, 757-759.

  • Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PAH.
    Direct visualisation of cytomegalovirus specific T-cell reconstitution following allogeneic bone marrow transplantation.
    Blood, 2001, 97, 1232-1240

  • Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabart S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JCW, Schey S, Mahendra P, Morgan G, Hale G, Waldmann H, Ruiz de Elvira M, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.
    In vivo Campath-1H prevents graft-versus-host disease following non myeloablative stem cell transplantation and limits transplant related mortality.
    Blood, 2000, 96, 2419-2425.

  • Tauro S, Dobie D, Richardson G, Hastings M, Mahendra P
    Recurrent penicillin resistant pneumococcal sepsis after matched unrelated donor transplantation for refractory T-NHL.
    Bone Marrow Transplantation, 2000,26, 1017-1019.

  • Tauro S, Toh V, Osman H, Mahendra P
    Varicella zoster meningoencephalitis following dermatomal zoster in an alloBMT patient: a role for early intravenous acyclovir in localised zoster infections.
    Bone Marrow Transplantation, 2000, 26, 795-796.

  • Mahendra P
    Hepatic veno-occlusive disease following stem cell transplantation.
    Thrombus, 1999, 3: 1-3.

  • Mahendra P
    Double autografting for multiple myeloma - is two better than one?
    Leukaemia and Lymphoma, 1999, 7: 29-34.

  • Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R
    Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies.
    British Journal of Haematology, 1998, 101: 483-486.

  • Scott M A, Gandhi M K, Jestice H K, Mahendra P, Bass G., Marcus R E.
    A trend towards an increased incidence of chronic graft-versus-host allogeneic following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Bone Marrow Transplantation, 1998,22: 273-276.

  • Rahman S L, Mahendra P, Nacheva E, Sinclair P, Arno J, Marcus R E.
    Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Bone Marrow Transplantation, 1998, 21: 955-956.

  • Somers L J, Shaw B, Lyn B E, McMillan A M, Mahendra P
    Meningeal myeloma in the absence of systemic disease and as the initial feature of disease progression.
    Clinical and Laboratory Haematology, 1998,20: 189-190

  • Hood I M, Mahendra P, McNeil K, Marcus R E.
    Hodgkin's Disease post cardiac transplantation: A report of two cases.
    Clinical and Laboratory Haematology, 1996, 18: 115-116

  • Mahendra P, Richards E M, Sinclair P, Marcus R E, Nacheva E.
    t(9;13)(q34;q12) translocation associated with myelodysplastic syndrome persisting 4 years post autologous bone marrow transplantation despite achieving haematological remission.
    Clinical and Laboratory Haematology, 1996, 18: 121-122

  • Richards E M, Jestice H K, Mahendra P, Scott M A, Marcus R E, Baglin T P.
    Measurement of reticulated platelets following peripheral blood progenitor cell and BMT: implications for marrow reconstitution and the use of thrombopoietin. Bone Marrow Transplantation, 1996, 17: 1029-1033

  • Mahendra P, Johnson D, Hood I M, Scott M A, Barker P, Bass G, Jestice H K, Bloxham D M, Boraks P, Wimperis J Z, Baglin T P, Marcus R E.
    High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
    Bone Marrow Transplantation, 1996, 17: 973-978

  • Mahendra P, Jacobson S K, Ager S, Bass G, Barker P, Johnson D, Baglin T P, Marcus R E.
    Short course intravenous antibiotics in conjunction with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or stem cell transplant recipients.
    Acta Haematologica, 1996, 96: 64-67.

  • Mahendra P, Hood I M, Lee M, Mewar D, Bass G, Flower C D R, Wilson C B, Marcus R E.
    Interstitial pneumonitis as a late complication after high-dose cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.
    Clinical Oncology, 1996, 8: 198-200.

  • Mahendra P, Keeling D M, Hood I M, Baglin T P, Marcus R E.
    Fatal thromboembolism in a patient with acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin.
    Clinical and Laboratory Haematology, 1996, 18:51-52.

  • Mahendra P, Hood I M, Bass G, Patterson P, Marcus R E.
    Severe haemosiderosis post allogeneic bone marrow transplantation.
    Haematological Oncology, 1996, 14; 33-35.

  • Mahendra P, Johnson D, Scott M A, Jestice H K, Ager S, Hood I M, Bass G, Barker P, Baglin T P, Marcus R E.
    Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
    Bone Marrow Transplantation, 1996, 17; 503-508.

  • Ager S, Mahendra P, Bass G, Baglin T P, Marcus R E.
    High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation; a dose:toxicity study.
    Bone Marrow Transplantation, 1996, 17; 335-340.

  • Mahendra P, Hood I M, Johnson D, Ethell M, Jestice H K, Scott M A, Barker P, Bass G, Baglin T P, Marcus R E.
    Autografting for multiple myeloma: a 5 year experience at a single institution.
    Bone Marrow Transplantation, 1995, 16: 759-763.

  • Ager S, Mahendra P, Jestice H K, Scott M A, Marcus R E.
    Non-cryopreserved peripheral stem cells for autologous transplantation.
    Bone Marrow Transplantation, 1995, 16: 633-634 (letter)

  • Scott M A, Ager S, Apperley J F, Jestice H K, Bloxham D M, Boraks P, Mahendra P, Marcus R E.
    Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.
    Leukemia and Lymphoma, 1995, 19: 479-484.

  • Ager S, Scott M A, Mahendra P, Richards M, Jestice H K, Boraks P, Baglin T P, Marcus R E.
    Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplantation, 1995, 16: 79-83.

  • MacGowan J R, Mahendra P, Ager S, Marcus R E.
    Thrombocytopenia and spontaneous rupture of the spleen associated with infectious mononucleosis.
    Clinical and Laboratory Haematology, 1995, 17: 93-94.

  • Scott MA, Ager S, Jestice H K, Mahendra P, Marcus R E.
    The failure to mobilise and harvest PBPCs does not necessarily preclude the use of high-dose therapy and autologous stem cell rescue.
    Bone Marrow Transplantation, 1995; 15: 487-488 (letter)

  • Mahendra P.
    In-vitro effects of cytokines on normal and myeloid leukaemic haemopoiesis.
    MD thesis, 1995; University of Glasgow.

  • Mahendra P, Harman K, Phillips M G, Gunning K, Marcus R E.
    Rapid progression of "retinoic acid syndrome" in the hypogranular variant of acuute promyelocytic leukaemia despite treatment with dexamethasone and conventional chemotherapy. Clinical and Laboratory Haematology, 1994; 16: 371-374.

  • Mahendra P, Ager S, Bedlow A J, Bloxham D, Green A R, Marcus R E.
    Two unusual neurological presentations of granulocytic sarcoma in Philadelphia positive chronic myeloid leukaemia.
    Leukemia and Lymphoma, 1994; 15: 351-355

  • Mahendra P, Bedlow A J, Ager S, Ancliff P J, Wraight E P, Marcus R E.
    Technetium (99mTc) labelled white cell scanning, 51Cr EDTA and 14C mannitol-labelled intestinal permeability studies: non-invasive methods of diagnosing intestinal graft-versus host disease.
    Bone Marrow Transplantation, 1994; 13: 835-837

  • Mahendra P, Barfoot R K, Bell J B G, Powles R, Treleaven J, Millar J L, Millar B C.
    TGFß1 and IL-4 have opposing effects on the proliferation of chronic phase chronic myeloid leukaemic cells stimulated by G-CSF in vitro.
    Leukemia and Lymphoma, 1994; 12: 449-455

  • Rege K, Powles R, Norton J, Mahendra P, Mitchell P, Agrawal S, Mehta J, Treleaven J.
    An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma.
    Leukemia and Lymphoma, 1993; 11: 305-307

  • Mahendra P.
    Pyruvate kinase deficiency, in association with glucose-6 phosphate dehydrogenase deficiency. British Medical Journal, 1992; 305: 760-762

  • McMullin M F, Mahendra P, Hain R, Barrett A J.
    Myelodysplasia as the initial presentation of Fanconi's anaemia in a phenotypically normal child.
    Clinical and Laboratory Haematology, 1991; 13: 387-389

  • Bashey A, Owen I, Lucas G F, Amphlett N W, Jones M M, Lawal A, McMullin M F, Mahendra P, Tyfield L A, Hows J M.
    Late onset immune pancytopenia following bone marrow transplantation.
    British Journal of Haematology, 1991; 78: 268-274

  • MacDonald D, Jian Y, Gordan A, Mahendra P, Oskam R, Palmer P, Franks C, Barrett A J.
    Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission.
    Leukaemia Research, 1990; 14: 967-973

NHS Patients

Centre for Clinical Haematology
Main Drive
Queen Elizabeth Hospital
Edgbaston
Birmingham B15 2TH

Secretary:
Angel Woodcock
Tel: 0(44) 121 627 2467
Fax: 0(44) 121 371 4397
Email Click Here

Private Patients

Priory Hospital
Priory Road Edgbaston Birmingham B5 7UG or Queen Elizabeth Hospital

Secretary:
Sheena Collins
Tel: 0(44) 121 446 1760
Tel: 0(44) 121 697 2443
Fax: 0(44) 121 446 1764
Email Click Here

© Copyright Prem Mahendra 2011

Designed by Medical Media